Full history for every metric is available with a Kvantra account
Imago BioSciences, Inc. (IMGO)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 0 | 0 | 0 | 0 |
| Operating profit | $m | -42 | -61 | |||||
| Net profit | $m | - | - | - | -11 | -18 | -42 | -63 |
| EPS reported | $ | -1.26 | -1.86 | |||||
| Operating cashflow per share | $ | -1.18 | -1.18 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.18 | -1.18 | |||||
| Free cash flow | $m | -40 | -52 | |||||
| Net debt | $m | -217 | -178 | |||||
| Book value equity | $m | 215 | 173 | |||||
| Book value per share | $ | 6.39 | 5.11 | |||||
| Number of shares | m | 33.58 | 33.77 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.71 | 7.04 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -20.03 | -23.25 | |||||
| EV/EBITDA LTM | x | -18.46 | -16.68 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -5.31% | -3.50% | |||||
| FCF Yield | % | -4.99% | -4.30% | |||||
| Quality | ||||||||
| ROE | % | -19.71% | -58.00% | |||||
| ROIC | % | -19.56% | -19.56% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.26 | 0.26 | |||||
| EBIT/Net interest | x | -133.74 | -133.74 | |||||
| Net debt/market cap | % | -27.30% | -14.67% | |||||
| Net debt/Equity | x | -1.01 | -1.03 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical firm specializing in the identification and advancement of small molecule product candidates. These candidates are designed to inhibit lysine-specific demethylase 1 (LSD1), an enzyme integral to the generation of blood cells within the bone marrow. The company's flagship therapeutic, bomedemstat, is presently undergoing Phase II clinical trials. It is being developed as a potential treatment for myeloproliferative neoplasms, a class of chronic bone marrow malignancies that includes conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. Established in 2012, Imago BioSciences is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Imago BioSciences, Inc. (IMGO)
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical firm specializing in the identification and advancement of small molecule product candidates. These candidates are designed to inhibit lysine-specific demethylase 1 (LSD1), an enzyme integral to the generation of blood cells within the bone marrow. The company's flagship therapeutic, bomedemstat, is presently undergoing Phase II clinical trials. It is being developed as a potential treatment for myeloproliferative neoplasms, a class of chronic bone marrow malignancies that includes conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. Established in 2012, Imago BioSciences is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free